Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation (DNKI-II)
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
About this trial
This is an interventional treatment trial for Acute Myelogenous Leukemia focused on measuring acute myelogenous leukemia, acute lymphoblastic leukemia, donor natural killer cells, HLA-haploidentical hematopoietic cell transplantation
Eligibility Criteria
Inclusion Criteria:
Patients with acute leukemia, which are refractory to standard treatment. Patients should be 17 years of age or older. The performance status of the patients should be 70 or over by Karnofsky scale. Patients should not have excessive hepatic dysfunction (bilirubin less than 3.0 mg/dl, AST less than 5 times the upper normal limit).
Patients should not have excessive renal dysfunction (creatinine less than 3.0 mg/dl).
Patients should not have clinically-evident cardiac or pulmonary dysfunction. Patients and donors must sign informed consent.
Exclusion Criteria:
Patients who are pregnant or lactating are not eligible.
Sites / Locations
- Asan Medical Center